Ligand Pharmaceuticals Incorporated (LGND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($13.16 Million) by net assets ($950.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ligand Pharmaceuticals Incorporated - Cash Flow Conversion Efficiency Trend (1994–2024)
This chart illustrates how Ligand Pharmaceuticals Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ligand Pharmaceuticals Incorporated (LGND) financial obligations for a breakdown of total debt and financial obligations.
Ligand Pharmaceuticals Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GCL System Integration Technology Co Ltd
SHE:002506
|
0.086x |
|
Yantai Moon Co Ltd
SHE:000811
|
0.046x |
|
Oceaneering International Inc
NYSE:OII
|
0.205x |
|
Baytex Energy Corp
TO:BTE
|
0.095x |
|
Liontown Resources Limited
F:LIS
|
-0.010x |
|
North Industries Group Red Arrow Co Ltd
SHE:000519
|
0.040x |
|
ASSECO POLAND GDR/1 ZY 1
F:SFBG
|
N/A |
|
General de Galerias Comerciales SOCIMI S.A.
MC:GGC
|
0.190x |
Annual Cash Flow Conversion Efficiency for Ligand Pharmaceuticals Incorporated (1994–2024)
The table below shows the annual cash flow conversion efficiency of Ligand Pharmaceuticals Incorporated from 1994 to 2024. For the full company profile with market capitalisation and key ratios, see Ligand Pharmaceuticals Incorporated (LGND) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $830.44 Million | $97.05 Million | 0.117x | +65.22% |
| 2023-12-31 | $700.91 Million | $49.58 Million | 0.071x | -69.34% |
| 2022-12-31 | $597.49 Million | $137.85 Million | 0.231x | +140.43% |
| 2021-12-31 | $821.16 Million | $78.80 Million | 0.096x | +24.73% |
| 2020-12-31 | $709.52 Million | $54.59 Million | 0.077x | +301.21% |
| 2019-12-31 | $767.23 Million | $-29.34 Million | -0.038x | -111.05% |
| 2018-12-31 | $560.91 Million | $194.06 Million | 0.346x | +54.80% |
| 2017-12-31 | $418.65 Million | $93.57 Million | 0.224x | +31.56% |
| 2016-12-31 | $370.85 Million | $63.00 Million | 0.170x | +23.93% |
| 2015-12-31 | $304.39 Million | $41.73 Million | 0.137x | -83.73% |
| 2014-12-31 | $24.41 Million | $20.57 Million | 0.843x | +102.05% |
| 2013-12-31 | $49.61 Million | $20.69 Million | 0.417x | +6760.24% |
| 2012-12-31 | $26.48 Million | $161.00K | 0.006x | +104.48% |
| 2011-12-31 | $8.65 Million | $-1.17 Million | -0.136x | -103.50% |
| 2010-12-31 | $-6.99 Million | $-27.07 Million | 3.872x | +142.89% |
| 2009-12-31 | $3.74 Million | $-33.80 Million | -9.028x | -553.70% |
| 2008-12-31 | $-10.37 Million | $-20.62 Million | 1.990x | +159.28% |
| 2007-12-31 | $29.11 Million | $-97.73 Million | -3.357x | +33.72% |
| 2006-12-31 | $27.35 Million | $-138.52 Million | -5.064x | -6585.05% |
| 2005-12-31 | $-110.42 Million | $8.37 Million | -0.076x | +0.84% |
| 2004-12-31 | $-75.32 Million | $5.75 Million | -0.076x | -2072.05% |
| 2003-12-31 | $70.73 Million | $274.00K | 0.004x | +101.14% |
| 2002-12-31 | $74.02 Million | $-25.11 Million | -0.339x | -198.64% |
| 2001-12-31 | $-57.88 Million | $-19.91 Million | 0.344x | -59.96% |
| 2000-12-31 | $-55.12 Million | $-47.35 Million | 0.859x | -63.65% |
| 1999-12-31 | $-25.60 Million | $-60.50 Million | 2.363x | -59.55% |
| 1998-12-31 | $-11.40 Million | $-66.60 Million | 5.842x | +1595.40% |
| 1997-12-31 | $34.30 Million | $-13.40 Million | -0.391x | +59.53% |
| 1996-12-31 | $34.50 Million | $-33.30 Million | -0.965x | +28.44% |
| 1995-12-31 | $28.10 Million | $-37.90 Million | -1.349x | -148.06% |
| 1994-12-31 | $26.30 Million | $-14.30 Million | -0.544x | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for r… Read more